BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 26432429)

  • 21. [Clinical characteristics of mycosis fungoides and Sézary syndrome].
    Krc L; Dobesová J; Bucek M; Dusek J; Macák J; Galuszková D; Jurysek O
    Vnitr Lek; 1997 May; 43(5):285-9. PubMed ID: 9601850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mycosis fungoides and Sézary syndrome : a systematic review].
    André F; Guenova E; Blanchard G
    Rev Med Suisse; 2022 Mar; 18(775):578-589. PubMed ID: 35353453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrastructural morphometry in the diagnosis of mycosis fungoides and Sézary's syndrome.
    Payne CM
    Clin Dermatol; 1991; 9(2):187-203. PubMed ID: 1747854
    [No Abstract]   [Full Text] [Related]  

  • 24. Cutaneous T-cell lymphoma.
    Lansigan F; Choi J; Foss FM
    Hematol Oncol Clin North Am; 2008 Oct; 22(5):979-96, x. PubMed ID: 18954747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome.
    Martinez XU; Di Raimondo C; Abdulla FR; Zain J; Rosen ST; Querfeld C
    Best Pract Res Clin Haematol; 2019 Sep; 32(3):239-252. PubMed ID: 31585624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values.
    Wood GS; Hong SR; Sasaki DT; Abel EA; Hoppe RT; Warnke RA; Morhenn VB
    J Am Acad Dermatol; 1990 Apr; 22(4):602-7. PubMed ID: 1690762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological milieu in mycosis fungoides and Sézary syndrome.
    Miyagaki T; Sugaya M
    J Dermatol; 2014 Jan; 41(1):11-8. PubMed ID: 24438139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging.
    Feng B; Jorgensen JL; Jones D; Chen SS; Hu Y; Medeiros LJ; Wang SA
    Mod Pathol; 2010 Feb; 23(2):284-95. PubMed ID: 19935642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Epidermotropic T lymphomas].
    Sigal-Nahum M; Brousse N; Belaïch S
    Rev Prat; 1987 May; 37(25):1423-31. PubMed ID: 3495856
    [No Abstract]   [Full Text] [Related]  

  • 30. Patch tests in Sézary syndrome and mycosis fungoides.
    Shupp DL; Winkelmann RK
    Contact Dermatitis; 1985 Sep; 13(3):180-5. PubMed ID: 4053598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sézary syndrome.
    Jothishankar B; Almazan T; Kim Y; Liauw S; Smith S; Kline J; Abdulla F
    Br J Haematol; 2019 Jul; 186(2):377-379. PubMed ID: 30937886
    [No Abstract]   [Full Text] [Related]  

  • 32. Mycosis fungoides/Sézary syndrome: report of an unusual case.
    Mehta A; Dhungel BM; Khan MF
    J Cutan Pathol; 2006 Sep; 33 Suppl 2():12-5. PubMed ID: 16972946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
    Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
    Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycosis Fungoides and Sézary Syndrome: An Update.
    Larocca C; Kupper T
    Hematol Oncol Clin North Am; 2019 Feb; 33(1):103-120. PubMed ID: 30497668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Memorials and mandates for cutaneous lymphomas.
    Heald PW
    Arch Dermatol; 2003 Jul; 139(7):926-8. PubMed ID: 12873891
    [No Abstract]   [Full Text] [Related]  

  • 36. Deciphering Tumor Cell Evolution in Cutaneous T-Cell Lymphomas: Distinct Differentiation Trajectories in Mycosis Fungoides and Sézary Syndrome.
    Jiang TT; Cao S; Kruglov O; Virmani A; Geskin LJ; Falo LD; Akilov OE
    J Invest Dermatol; 2024 May; 144(5):1088-1098. PubMed ID: 38036289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current pathogenetic aspects of Sézary syndrome and mycosis fungoides].
    Dummer R; Willers J; Döbbeling U; Burg G
    Hautarzt; 2001 Mar; 52(3):189-92. PubMed ID: 11284062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
    Leroy S; Dubois S; Tenaud I; Chebassier N; Godard A; Jacques Y; Dréno B
    Br J Dermatol; 2001 May; 144(5):1016-23. PubMed ID: 11359391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycosis fungoides and sezary syndrome: an update.
    Kim EJ; Lin J; Junkins-Hopkins JM; Vittorio CC; Rook AH
    Curr Oncol Rep; 2006 Sep; 8(5):376-86. PubMed ID: 16901399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.